These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 4681306)

  • 21. Long-term application of 1,25-dihydroxyvitamin D3. Effect on its serum level in dialysis patients and on the calcium content of various organs in experimental uremia.
    Saupe J; Hirschberg R; von Herrath D; Schaefer K
    Contrib Nephrol; 1988; 65():115-22. PubMed ID: 3168458
    [No Abstract]   [Full Text] [Related]  

  • 22. Treatment of renal osteodystrophy with Dialume recipes.
    Bushman MC
    Nephrol Nurse; 1983; 5(2):26-8, 30. PubMed ID: 6551681
    [No Abstract]   [Full Text] [Related]  

  • 23. Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease.
    Salusky IB; Foley J; Nelson P; Goodman WG
    N Engl J Med; 1991 Feb; 324(8):527-31. PubMed ID: 1992306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Calcinosis universalis with hyperphosphataemia--successful treatment with phosphorus deprivation].
    Yoshikawa S; Shoji T; Ono A; Amagai H; Kamimaki Y; Takematsu H; Hosokawa O
    Nihon Seikeigeka Gakkai Zasshi; 1985 Mar; 59(3):293-302. PubMed ID: 4020226
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Osteomalacia from phosphate-binding substances (author's transl)].
    Emanuelli C; Borghi M; Pecchini F
    Ateneo Parmense Acta Biomed; 1975; 46(6):577-87. PubMed ID: 1222067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Opinionnaire survey on the treatment of renal osteodystrophy in Japan].
    Morii H
    Nihon Jinzo Gakkai Shi; 1983 Apr; 25(4):439-47. PubMed ID: 6620696
    [No Abstract]   [Full Text] [Related]  

  • 27. [Calcium carbonate for the treatment of hyperphosphatemia in chronic hemodialysis patients].
    Kiss D; Battegay M; Meier C; Lyrer A
    Schweiz Med Wochenschr; 1990 Mar; 120(9):295-8. PubMed ID: 2315655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Calcium and phosphorus in diet therapy of uremia.
    Schoolwerth AC; Engle JE
    J Am Diet Assoc; 1975 May; 66(5):460-4. PubMed ID: 1123506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Use of sucralfate (Ulcar) as phosphorus chelator in hemodialysis patients: preliminary results].
    Bui-Quang D; Baron M; Picaud D
    Nephrologie; 1985; 6(5):246. PubMed ID: 3841582
    [No Abstract]   [Full Text] [Related]  

  • 30. Diabetic patients on CAPD need less aluminum hydroxide as a phosphate binder than non-diabetics.
    Macia M; Coronel F; Torrente J; Sanchez A; Tornero F; Barrientos A
    Adv Perit Dial; 1990; 6():50-2. PubMed ID: 1982839
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment and prevention of uremic osteodystrophy.
    Giovannetti S; Barsotti G; Gretz N; Kraft K
    Contrib Nephrol; 1989; 72():66-72. PubMed ID: 2743774
    [No Abstract]   [Full Text] [Related]  

  • 32. Prevention of osteitis fibrosa, aluminium bone disease and soft-tissue calcification in dialysis patients: a long-term comparison of moderate doses of oral calcium +/- Mg(OH)2 vs Al(OH)3 +/- 1 alpha OH vitamin D3.
    Morinière P; Boudailliez B; Hocine C; Belbrik S; Renaud H; Westeel PF; Solal MC; Fournier A
    Nephrol Dial Transplant; 1989; 4(12):1045-53. PubMed ID: 2517325
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Aluminum hydroxide treatment of hyperphosphatemia in uremia].
    Bergquist-Poppen M; Bergström J; Wallin R
    Lakartidningen; 1972 May; 69(19):2319-20. PubMed ID: 5035811
    [No Abstract]   [Full Text] [Related]  

  • 34. [Disorders of calcium phosphate homeostasis in patients with intermittent hemodialysis therapy].
    Pogglitsch H; Holzer H; Giessauf W; Stöckl G
    Wien Med Wochenschr; 1972 May; 122(22):311-7. PubMed ID: 5045838
    [No Abstract]   [Full Text] [Related]  

  • 35. Assessing the benefit of changing aluminium hydroxide schedule on anaemia and serum phosphorus control.
    Cannata JB; Suarez Suarez C; Rogrigues Suarez C; Cuesta V; Sanz-Medel A; Peral V; Herrera J
    Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():410-4. PubMed ID: 3991533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. How KDIGO will (or will not) influence the management of hyperphosphatemia.
    Kovesdy CP
    Semin Dial; 2011; 24(1):35-6. PubMed ID: 21338391
    [No Abstract]   [Full Text] [Related]  

  • 37. Correction of high serum aluminium in a patient on maintenance haemodialysis.
    Wallace MR
    N Z Med J; 1981 May; 93(684):335-7. PubMed ID: 6942294
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of dihydrotachysterol (DHT) on calcium metabolism in uremia.
    Asad S; Ellis K; Cohn S; Letter J
    Trans Am Soc Artif Intern Organs; 1974; 20A():142-7. PubMed ID: 4450332
    [No Abstract]   [Full Text] [Related]  

  • 39. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
    Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of aluminium hydroxide orally on calcium, phosphorus and aluminium metabolism in normal subjects.
    Cam JM; Luck VA; Eastwood JB; de Wardener HE
    Clin Sci Mol Med; 1976 Oct; 51(4):407-14. PubMed ID: 971581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.